Rasio utang jangka dawa marang modal Poseida Corp (PSTX)

Poseida Therapeutics (PSTX) develops innovative oncology treatments based on non-viral platforms, receiving regular payments from major pharmaceutical partners. The business remains independent of economic fluctuations, as its success is driven by clinical trial results. The indicator stands at 0.93. The price history confirms the high value of the company's technologies, which led to its full acquisition by a global industry leader.

Poseida Therapeutics (PSTX) invests in sustainable gene therapy technologies and green chemistry principles. The ratio is calculated as the proportion of liabilities with a maturity of over one year to total equity. This metric determines financial leverage and the degree of business autonomy from long-term borrowings. High values signal over-leverage risks when scaling laboratories. By analyzing the long-term debt-to-equity trend, an investor assesses the sustainability of the company's development strategy.